CMCaitlyn McComb

Caitlyn McComb

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Caitlyn McComb has a total of 55 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    GD2 Induction by Combination Chromatin-Directed Inhibitors Enhances Targeting of Ewing Sarcoma and Osteosarcoma by CAR T Cells

    by Justin R. Sperlazza, Kevin C. Field, Caitlyn McComb, Elisa Landoni, Sara K. Peterson, Anna Jin, Austin J. Hepperla, Rachel L. Chambers, William C. Zamboni, Barbara Savoldo, et al.

    Adoptive cellular therapies depend on the adequate expression of target antigens on tumors. The disialoganglioside GD2, a target of chimeric antigen receptor (CAR) T cells (GD2.CAR T cells) and monoclonal antibodies, is variably expressed in Ewing sarcoma and osteosarcoma. We investigated the ability of chromatin-directed small molecules to enhance tumor GD2 and sensitize tumors to GD2.CAR T cells. Although the EZH2 inhibitor tazemetostat increased GD2 levels in culture and in xenografted mice, tazemetostat treatment was unable to maintain sufficient tumor GD2 levels necessary to enable tumor control in a metastatic xenograft model. We performed a screen of chromatin-directed small molecules to identify additional compounds capable of regulating tumor GD2 and identified multiple compounds, including the HDAC inhibitor entinostat and the DOT1L inhibitor pinometostat. Both compounds greatly enhanced tumor GD2 expression by tazemetostat in culture but did not limit CAR T-cell activity. In multiple xenograft models, the combination of tazemetostat and entinostat resulted in enhanced tumor GD2 expression and led to long-term tumor control by GD2.CAR T cells. These data offer preclinical support for the incorporation of chromatin-directed inhibitors into ongoing CAR T-cell trials for Ewing sarcoma and osteosarcoma.

  • Pediatric autoimmune hemolytic anemia is associated with a high incidence of underlying immune disorders

    by Emily M. Harris, MacGregor Steele, Tatiana Kalashnikova, Sherif M. Badawy, Sureka Pavalagantharajah, Kirsty Hillier, Robert J. Klaassen, Joshua A. Kalter, Jennifer A. Rothman, Caitlyn McComb, et al.

    Pediatric autoimmune hemolytic anemia (AIHA) is a heterogeneous disease with significant morbidity due to the underlying condition and its treatment. Evidence-based guidelines for evaluation and management are lacking. Data from 399 patients with AIHA followed at 15 pediatric centers were collected to identify factors associated with secondary diagnoses, recurrent/chronic course, therapeutic efficacy, and mortality. Most had AIHA associated with secondary diagnoses including Evans syndrome (142/385 [37%]), other autoimmunity (86/392 [22%]), and inborn errors of immunity (IEI; 68/379 [18%]). Of 305 patients tested, 82% had abnormal functional immune results. Genetic testing for IEI was performed in 109 of 348 patients (31%), with pathogenic findings identified in 32% of those tested. Patients with IEI or other autoimmunity more frequently had abnormal immunoglobulin and complement testing. Prevalence of IEI was not different between those presenting with and without infection. The median number of treatments for the first AIHA episode was 2 (range, 0-17). Of those with warm AIHA, 31% received steroid-sparing therapy during the first episode. Patients with recurrent AIHA (42%) had a higher rate of abnormal immune tests (odds ratio [OR], 2.29; P = .012), Evans syndrome (OR, 4.85; P< .001), IEI (OR, 3.88; P< .001), and other autoimmune disorders (OR, 3.29; P< .001). With a median follow-up of 4.9 years (range, 0-19.4), 72 of 257 (28%) with warm AIHA continued to have active disease on treatment. Of the 399 patients, 10 died, all of whom had secondary diagnoses. Expansive immune evaluation, monitoring, and targeted treatments directed at immune diagnoses are needed for pediatric AIHA, highlighting the need for evidence-based pediatric AIHA guidelines.


  • Inclusion of Thiotepa in Myeloablative Regimens Improves Donor Chimerism in Children with Inborn Errors of Immunity or Inherited Metabolic Disorders

    by Caitlyn McComb, Vinita Pai, Joseph Stanek, Alexander W. Rankin, Margaret Lamb, Nabanita Bhunia, Rajinder Bajwa, Rolla Abu‐Arja, Hemalatha G. Rangarajan